poisar

Stock

Lantheus Holdings, Inc. LNTH

$105.21+1.49%

Overview

LNTH market data

Price History

LNTH price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
24.52
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$3.41
Diluted earnings per share over the trailing twelve months.
Beta
-0.00
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$47.25 – $111.86
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $6.8K · P/B 4.05 · P/S 4.42.

Company news

10 captured
Truist Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $125Benzinga · Jul 16, 2026, 4:16 PM
Mizuho Maintains Market Outperform on Lantheus Holdings, Raises Price Target to $120Benzinga · Jul 15, 2026, 6:30 PM
B. Riley Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $129Benzinga · Jul 9, 2026, 1:55 PM
FDA Manufacturing Issues Delay Lantheus' Tumor Imaging KitBenzinga · Jun 29, 2026, 1:55 PM
Citizens Reiterates Market Outperform on Lantheus Holdings, Maintains $115 Price TargetBenzinga · Jun 29, 2026, 1:15 PM
Lantheus Holdings Receives FDA Complete Response Letter For LNTH-2501 Due To Manufacturing Facility Issues; No Safety Or Efficacy Concerns IdentifiedBenzinga · Jun 26, 2026, 8:05 PM
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsightGlobenewswire Inc · Jun 10, 2026, 5:15 PM
Mizuho Maintains Outperform on Lantheus Holdings, Raises Price Target to $115Benzinga · May 27, 2026, 2:15 PM
'Lantheus Weighs Potential $7 Billion Sale Following Offer From Curium' - Bloomberg NewsBenzinga · May 22, 2026, 8:25 PM
Truist Securities Reiterates Buy on Lantheus Holdings, Raises Price Target to $115Benzinga · May 11, 2026, 3:07 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock